Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDTX NASDAQ:CCCC NASDAQ:IPSC NASDAQ:KMDA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$1.85+1.9%$2.09$1.60▼$4.94$105.72M3.251.20 million shs251,921 shsCCCCC4 Therapeutics$3.80+6.1%$3.91$1.69▼$5.17$419.61M2.92.74 million shs1.98 million shsIPSCCentury Therapeutics$2.22+1.1%$2.28$0.44▼$3.04$399.48M1.551.54 million shs361,202 shsKMDAKamada$7.29+2.8%$7.46$6.50▼$9.35$419.08M0.8559,716 shs12,759 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics+1.12%-4.74%+9.04%-42.54%-42.17%CCCCC4 Therapeutics-2.98%-8.67%-13.32%+14.74%+54.31%IPSCCentury Therapeutics-2.67%-0.45%-4.37%-4.78%+277.07%KMDAKamada+0.57%-1.12%-3.01%-12.68%-4.83%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDTXBlack Diamond Therapeutics$1.85+1.9%$2.09$1.60▼$4.94$105.72M3.251.20 million shs251,921 shsCCCCC4 Therapeutics$3.80+6.1%$3.91$1.69▼$5.17$419.61M2.92.74 million shs1.98 million shsIPSCCentury Therapeutics$2.22+1.1%$2.28$0.44▼$3.04$399.48M1.551.54 million shs361,202 shsKMDAKamada$7.29+2.8%$7.46$6.50▼$9.35$419.08M0.8559,716 shs12,759 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDTXBlack Diamond Therapeutics+1.12%-4.74%+9.04%-42.54%-42.17%CCCCC4 Therapeutics-2.98%-8.67%-13.32%+14.74%+54.31%IPSCCentury Therapeutics-2.67%-0.45%-4.37%-4.78%+277.07%KMDAKamada+0.57%-1.12%-3.01%-12.68%-4.83%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDTXBlack Diamond Therapeutics 2.73Moderate Buy$9.83432.97% UpsideCCCCC4 Therapeutics 2.57Moderate Buy$7.75102.09% UpsideIPSCCentury Therapeutics 2.43Hold$4.75114.45% UpsideKMDAKamada 3.00Buy$12.0065.08% UpsideCurrent Analyst Ratings BreakdownLatest BDTX, CCCC, IPSC, and KMDA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026CCCCC4 Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/13/2026BDTXBlack Diamond Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (D-)7/2/2026IPSCCentury Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)6/25/2026KMDAKamada Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B) ➝ Buy (B-)5/27/2026IPSCCentury Therapeutics MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$8.005/22/2026BDTXBlack Diamond Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform5/22/2026BDTXBlack Diamond Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/22/2026BDTXBlack Diamond Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/18/2026BDTXBlack Diamond Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/15/2026KMDAKamada Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)4/29/2026BDTXBlack Diamond Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 7/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDTXBlack Diamond Therapeutics$70M1.51$0.54 per share3.39$1.97 per share0.94CCCCC4 Therapeutics$35.95M11.80N/AN/A$2.65 per share1.45IPSCCentury Therapeutics$109.16M3.66$0.01 per share169.17$1.82 per share1.22KMDAKamada$180.46M2.32$0.63 per share11.55$4.68 per share1.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDTXBlack Diamond Therapeutics$22.37M-$0.77N/AN/AN/AN/A-30.18%-23.91%8/6/2026 (Estimated)CCCCC4 Therapeutics-$104.99M-$1.19N/AN/AN/A-297.76%-50.68%-33.22%8/6/2026 (Estimated)IPSCCentury Therapeutics-$9.58M-$1.14N/AN/AN/AN/A-49.89%-37.42%8/13/2026 (Estimated)KMDAKamada$20.20M$0.3520.7711.920.6511.21%7.73%5.41%8/12/2026 (Estimated)Latest BDTX, CCCC, IPSC, and KMDA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2026Q2 2026IPSCCentury Therapeutics-$0.11N/AN/AN/A$2.17 millionN/A8/12/2026Q2 2026KMDAKamada$0.12N/AN/AN/A$50.84 millionN/A8/6/2026Q2 2026BDTXBlack Diamond Therapeutics-$0.18N/AN/AN/AN/AN/A8/6/2026Q2 2026CCCCC4 Therapeutics-$0.23N/AN/AN/A$8.20 millionN/A5/14/2026Q1 2026KMDAKamada$0.12$0.07-$0.05$0.07$46.72 million$45.24 million5/13/2026Q1 2026IPSCCentury Therapeutics-$0.15-$0.11+$0.04-$0.11$2.87 millionN/A5/12/2026Q1 2026CCCCC4 Therapeutics-$0.2506-$0.20+$0.0506-$0.20$4.42 million$6.15 million5/7/2026Q1 2026BDTXBlack Diamond Therapeutics-$0.18-$0.16+$0.02-$0.16$25.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBDTXBlack Diamond TherapeuticsN/AN/AN/AN/AN/ACCCCC4 TherapeuticsN/AN/AN/AN/AN/AIPSCCentury TherapeuticsN/AN/AN/AN/AN/AKMDAKamada$0.192.61%N/A54.29%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDTXBlack Diamond TherapeuticsN/A8.468.46CCCCC4 TherapeuticsN/A9.009.00IPSCCentury TherapeuticsN/A10.2510.25KMDAKamadaN/A3.331.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDTXBlack Diamond Therapeutics95.47%CCCCC4 Therapeutics78.81%IPSCCentury Therapeutics50.20%KMDAKamada20.38%Insider OwnershipCompanyInsider OwnershipBDTXBlack Diamond Therapeutics9.29%CCCCC4 Therapeutics5.60%IPSCCentury Therapeutics2.40%KMDAKamada36.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDTXBlack Diamond Therapeutics9057.30 million51.98 millionOptionableCCCCC4 Therapeutics150110.57 million104.38 millionOptionableIPSCCentury Therapeutics170180.35 million176.03 millionOptionableKMDAKamada36057.51 million36.75 millionOptionableBDTX, CCCC, IPSC, and KMDA HeadlinesRecent News About These CompaniesKamada (NASDAQ:KMDA) Share Price Crosses Below Two Hundred Day Moving Average - Should You Sell?July 21 at 3:21 AM | americanbankingnews.comKamada (NASDAQ:KMDA) Stock Passes Below 200 Day Moving Average - Here's WhyJuly 21 at 3:19 AM | marketbeat.comKamada jumps on $50m source plasma dealJuly 20 at 6:32 PM | en.globes.co.ilEKamada Ltd.: Kamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived TherapiesJuly 20 at 8:30 AM | finanznachrichten.deKamada Announces a Three-Year $50 Million Sales Agreement to Supply Plasma to a Leading Biopharmaceutical Company focused on Plasma-derived TherapiesJuly 20 at 7:00 AM | globenewswire.comKamada Showcases New CYTOGAM Data from 2026 ISHLT Meeting, Signaling Potential Uptick in Transplant UseJuly 13, 2026 | tipranks.comKamada Highlights CYTOGAM® Study Results Presented at the 2026 ISHLT Annual MeetingJuly 13, 2026 | globenewswire.comY.D. More Investments Ltd Lowers Stock Holdings in Kamada Ltd. $KMDAJuly 13, 2026 | marketbeat.comKamada Ltd Stock GuidanceJuly 3, 2026 | benzinga.comKamada Posts Solid Q1 2026 Results and Reaffirms Full-Year Guidance as Plasma Expansion AdvancesJune 29, 2026 | theglobeandmail.comKamada Sets August 5, 2026 Annual General Meeting to Vote on Board, Option Plan and AuditorJune 18, 2026 | tipranks.comKamada: Undervalued, Yet Execution Risks Keep It A HoldJune 2, 2026 | seekingalpha.comKamada Wins FDA Nod for New In‑House Rabies Antibody Testing LabJune 1, 2026 | tipranks.comKamada Announces FDA Approval of its New In-House Rabies Virus Neutralization Testing LaboratoryJune 1, 2026 | globenewswire.comKamada Ltd Earnings Call Balances Growth And RisksMay 19, 2026 | tipranks.comKamada Ltd. (NASDAQ:KMDA) Q1 2026 Earnings Call TranscriptMay 14, 2026 | insidermonkey.comKamada (KMDA) Q1 2026 Earnings TranscriptMay 13, 2026 | finance.yahoo.comKamada (KMDA) misses Q1 earnings and revenue estimatesMay 13, 2026 | msn.comKamada Ltd. (KMDA) Q1 2026 Earnings Call TranscriptMay 13, 2026 | seekingalpha.comKamada (KMDA) Q1 Earnings: How Key Metrics Compare to Wall Street EstimatesMay 13, 2026 | zacks.comKamada Reports First Quarter 2026 Financial Results and Affirms 2026 Annual Guidance; Expecting Significantly Stronger Remainder of the YearMay 13, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBDTX, CCCC, IPSC, and KMDA Company DescriptionsBlack Diamond Therapeutics NASDAQ:BDTX$1.84 +0.04 (+1.93%) As of 02:11 PM Eastern This is a fair market value price provided by Massive. Learn more.Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.C4 Therapeutics NASDAQ:CCCC$3.80 +0.22 (+6.09%) As of 02:11 PM Eastern This is a fair market value price provided by Massive. Learn more.C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Century Therapeutics NASDAQ:IPSC$2.22 +0.03 (+1.14%) As of 02:11 PM Eastern This is a fair market value price provided by Massive. Learn more.Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.Kamada NASDAQ:KMDA$7.28 +0.20 (+2.75%) As of 02:07 PM Eastern This is a fair market value price provided by Massive. Learn more.Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Is Planning a New AI Chip. Here's Why It Matters Ahead of Earnings Industrial and Utility Giants Boost Dividends as Data Center Tailwinds Build IREN’s $2.8 Billion AI Contract Haul Changes the Stock’s Story 2 ETFs to Access the World's Best-Performing Stock Markets In 2026 Microsoft's AI Bet Could Rewrite AMD's Growth Story Buy, Hold, or Wait: 3 Small-Cap Stocks Telling Different Stories The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino's Stock Serving Up a Buying Opportunity? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
